Shufeng Xingbi Therapy Restores Immune Balance in AR Rat Model

Study Background and Research Question

Allergic rhinitis (AR) is a chronic, non-infectious inflammatory condition of the nasal mucosa, marked by symptoms such as sneezing, nasal congestion, and itching. Its prevalence exceeds 10% globally and continues to rise, negatively impacting quality of life and imposing economic burdens on patients. The pathogenesis of AR is closely linked to an imbalance in T helper cell (Th1/Th2) immune responses, with excessive Th2 activity driving IgE-mediated hypersensitivity. Current therapeutic strategies—antihistamines, glucocorticoids, and leukotriene antagonists—provide symptomatic relief but are associated with side effects, especially in pediatric populations, and do not comprehensively address immune dysregulation or the underlying microbiota alterations. Given the associations between the gut microbiome, immune maturation, and allergic diseases, the "hygiene hypothesis" posits that early environmental and microbial exposures protect against atopic disorders. This has prompted interest in therapies that modulate both immune balance and microbiota composition. The present study (Yan et al., 2025) investigates the efficacy and mechanism of Shufeng Xingbi Therapy (SFXBT)—a traditional Chinese medicine protocol—on Th1/Th2 immune balance and intestinal flora in an ovalbumin-induced AR rat model. The central research question is whether SFXBT can correct immune imbalances and beneficially remodel the gut microbiome, thereby alleviating AR pathology.

Key Innovation from the Reference Study

The study's primary innovation lies in its dual mechanistic approach: simultaneously quantifying immunological and microbiome outcomes in a controlled preclinical AR model. Unlike prior studies that focus predominantly on symptomatic relief or singular immune markers, this work characterizes:

• Quantitative shifts in Th1/Th2 immune markers at both mRNA and protein levels (STAT5, STAT6, GATA3, IL-4).
• Comprehensive microbiota profiling of colonic contents, assessing both phylum and genus-level changes.
• Integration of behavioral, histopathological, and biochemical data to link clinical endpoints with mechanistic changes.

This integrated design enables the identification of SFXBT’s immunomodulatory effects as being closely related to beneficial alterations in gut microbial communities, particularly short-chain fatty acid (SCFA) production.

Methods and Experimental Design Insights

The study utilized 32 clean male Sprague-Dawley rats, divided into four groups: control, AR (OVA-induced), antibiotic + SFXBT, and acetic acid + SFXBT. Key methodological features include:

• AR induction via ovalbumin (OVA) sensitization, a widely used model recapitulating Th2-driven airway inflammation.
• Intervention with SFXBT (both oral and nasal formulations) following AR induction, with an antibiotic pre-treatment arm to probe microbiota dependencies.
• Behavioral scoring for AR symptoms, histological assessment (H&E staining) of nasal mucosa, and multi-modal molecular analyses:
• 16S rDNA sequencing for gut microbiota profiling.
• ELISA for serum IgE, IL-4, and SCFAs.
• RT-qPCR and Western Blot for nasal mucosa mRNA and protein expression of STAT5, STAT6, GATA3, and IL-4.

This design enables robust correlation between immune markers, microbial shifts, and clinical phenotype.

Protocol Parameters

• AR induction: Ovalbumin sensitization and challenge; follow rat weight and age guidelines as described in the reference study.
• SFXBT administration: Oral Shufeng Xingbi recipe and topical Xingbi gel nasal drops; dosage and timing as per protocol details.
• Antibiotic pre-treatment: Where relevant, antibiotic regimen commenced before SFXBT to assess microbiota-dependent effects.
• Sample collection: Endpoints include behavioral scoring, tissue harvesting for histology, and molecular analyses (16S rDNA, ELISA, RT-qPCR, Western blot).

Core Findings and Why They Matter

Several significant outcomes were reported:

• Reduced AR symptoms and nasal mucosal inflammation: Both behavioral scores and histology revealed significant improvement in the SFXBT groups compared to AR-only rats (Yan et al., 2025).
• Restoration of Th1/Th2 balance: SFXBT led to decreased serum IgE and IL-4 (key Th2 cytokines), alongside reduced mRNA and protein expression of STAT5, STAT6, and GATA3—key transcriptional regulators of Th2 polarization.
• Gut microbiota remodeling: There was a significant increase in beneficial Firmicutes and genera such as Lactobacillus, Romboutsia, Allobaculum, and Dubosiella, with a decrease in Bacteroidetes. This shift coincided with elevated SCFA levels, indicative of enhanced microbial metabolism and anti-inflammatory potential.

Collectively, these findings suggest that SFXBT not only suppresses local nasal inflammation but also acts systemically via gut–immune axes, providing a mechanistic bridge between immune modulation and microbiota restoration.

Comparison with Existing Internal Articles

Recent literature reviews, such as "Shufeng Xingbi Therapy Modulates Immunity and Microbiota in AR Rats", reinforce the dual-action model demonstrated in this study, highlighting that immune modulation and microbiota restoration can synergistically improve allergic outcomes. This approach aligns with broader mechanistic research in the field of RNA/DNA structure interaction studies, where tools like aminoglycoside antibiotics—including Neomycin sulfate—are employed for mechanistic interrogation of nucleic acid–protein and host–microbe interactions (as discussed in related internal analysis). Furthermore, advanced studies on Neomycin sulfate highlight its unique ability to probe ion channel function and nucleic acid structures, expanding the toolkit for exploring immune and microbiota interactions that underpin allergic inflammation.

Limitations and Transferability

While the findings demonstrate clear improvements in AR symptoms and mechanistic endpoints, several limitations should be noted:

• The use of a single animal model may not capture the full complexity of human AR or microbiota–immune interactions.
• The specific components of the SFXBT responsible for these effects were not dissected, and batch-to-batch variability may affect reproducibility.
• Antibiotic pre-treatment alters the baseline microbiota, which may not reflect typical clinical scenarios.
• Translation to clinical populations, especially children, will require careful safety and efficacy studies.

Nevertheless, the integrative approach provides a valuable framework for future translational research.

Research Support Resources

For investigators interested in advancing studies of immune modulation, gut microbiota, or nucleic acid–protein interactions in allergic models, high-purity research reagents are essential. For example, Neomycin sulfate (SKU B1795) is a well-characterized aminoglycoside antibiotic capable of disrupting nucleic acid structures, modulating ion channels, and serving as a tool in RNA/DNA interaction studies. Its mechanism—such as inhibition of hammerhead ribozyme cleavage, disruption of HIV-1 Tat–TAR RNA interactions, and voltage-dependent ryanodine receptor channel blocking—has been validated in diverse molecular assays. Researchers can reference APExBIO’s product specifications to design robust protocols for mechanistic studies involving immune and microbial pathways.